A topoisomerase I inhibitor with a response rate of 14-33% in recurrent ovarian carcinoma in standard 5 day treatment regimen.
Routes:Intravenous infusion, oral
Bioavailability 31.4% and protein binding of 35%.
Hepatic metabolism with half-life 2-3 hours.
Renal excretion.
A chemotherapeutic agent that is a topoisomerase inhibitor.
A water-soluble derivative of camptothecin.
Used to treat ovarian cancer and lung cancer.
The first topoisomerase I inhibitor for oral use.
Weekly treatment results in decreased myelosuppression with response rates in recurrent ovarian cancer similar to daily treatment schedule.
Has a response rate of 28% when used neoadjuvantly in newly diagnosed medulloblastoma and CNS PNET.